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ABSTRACT
Objectives: The association between methylenetetrahydrofolate reductase gene polymorphisms and unexplained recurrent 
miscarriage is elusive. The recommendations for improving pregnancy outcomes in these patients keep changing based 
on the available evidence. The aim of this study is to analyze the impact of low molecular weight heparin on obstetric 
outcomes of recurrent miscarriage patients complicated with methylenetetrahydrofolate reductase gene polymorphism.
Material and methods: We reviewed medical records of 121 patients with a history of recurrent miscarriage complicated 
by methylenetetrahydrofolate reductase gene polymorphisms, retrospectively. From among them, 68 patients were treated 
only with folic acid and iron. The remaining 53 patients were treated with folic acid, iron and prophylactic doses of low 
molecular weight heparin. The subsequent pregnancy outcomes of these patients were noted.
Results: The live birth rate was higher in patients with anticoagulant therapy than in patients without anticoagulant therapy 
(48.5% vs. 69.8%, respectively, p: 0.015) and the congenital anomaly rate was lower in anticoagulant therapy group (17.6% 
vs. 3.8%, respectively, p: 0.022). The other obstetric outcomes were found to be similar between the two groups.
Conclusions: The current study demonstrated that low molecular weight heparin improved the live birth rates among unex-
plained recurrent miscarriage patients complicated with methylenetetrahydrofolate reductase gene polymorphisms. How-
ever, the routine use of low molecular weight heparin did not improve the late pregnancy complications in these selected 
patients in the eastern region of our country. Further studies are needed to discriminate the effect of anticoagulation on 
the live birth rate of each of methylenetetrahydrofolate reductase gene polymorphism type.
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INTRODUCTION
Recurrent miscarriage (RM) is a major obstetric problem 
that is challenging for both: the patients as well as the cli-
nicians. Approximately 3% of women in reproductive age 
experience recurrent pregnancy loss [1, 2]. The etiology is 
multifactorial and includes chromosomal abnormalities, 
uterine anatomical pathologies, endocrine dysfunctions, 
maternal autoimmune disorders, acquired or inherited 
thrombophilia and environmental causes [3]. Despite the 
availability of diagnostic methods such as hysteroscopy, 
hysterosalpingography, antiphospholipid antibody testing 
or parental karyotyping, the underlying pathology remains 
unidentified in 50% of cases which are defined as unex-
plained RMs [4]. Multiple pregnancy loss is also a risk factor 
for intrauterine growth restriction (IUGR), preterm delivery 
and fetal abnormalities [5]. Finally, a cohort study reports 
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that patients with recurrent miscarriage represent a popula-
tion that is at high risk for obstetric complications that re-
quire a close surveillance during the antenatal period [5, 6].
Increased homocysteine concentration in maternal 
circulation is associated with unexplained RM. Hyperho-
mocysteinemia was detected in approximately 30% of RM 
patients [7, 8]. Since 5’,10’-methylenetetrahydrofolate re-
ductase (MTHFR) enzyme encoded by the MTHFR gene 
is necessary for the conversion of homocysteine to me-
thionine, the reduction in enzyme activity results in a mild 
elevation of blood homocysteine levels [11]. The single 
nucleotide polymorphism of C677T and A1298C are the 
most commonly identified forms of MTHFR gene polymor-
phism. Patients homozygous for MTHFR C677T showed 
about 30% of normal enzyme activity while heterozygosity 
demonstrates 65% of normal enzyme activity. In contrast, 
such reduction in enzyme activity in women with MTHFR 
A1298C polymorphism was not demonstrated [9, 10]. It 
would be reasonable then to assume that the A1298C type 
of polymorphism does not influence the homocysteine 
levels, hence it should not be linked to unexplained RM. 
Indeed, a recent meta-analysis has found that there is no 
relation between MTHFR A1298C polymorphism and un-
explained recurrent pregnancy loss. However, it has also 
been found that the MTHFR C677T type was a contributor 
for recurrent pregnancy loss but in East Asians only [12, 13]. 
The debate on MTHFR gene polymorphism and unexplained 
RM remains elusive.
There is also no consensus about the use of low mo-
lecular weight heparin (LMWH) for preventing miscarriag-
es. In recent Cochrane meta-analysis the authors did not 
recommend anticoagulants in RM patients beyond those 
complicated with inherited thrombophilia. They also sug-
gested that pregnancy complications like preterm delivery, 
preeclampsia, IUGR and congenital abnormalities were not 
significantly affected by the use of aspirin or LMWH [14]. 
Despite this, empirical therapy for unexplained RM patients 
in form of a low dose aspirin and prophylactic doses of 
LMWH has been a widespread clinical practice in several 
clinics around Turkey [15]. 
OBJECTIVES
We performed a retrospective study to evaluate the 
impact of LMWH on obstetric outcomes of recurrent miscar-
riage patients complicated with MTHFR gene polymorphism 
in our tertiary referral hospital in eastern Turkey.
MATERIAL AND METHODS
This single center retrospective study was conducted at 
Yuzuncu Yıl University Medical Faculty, Obstetrics and Gyne-
cology clinic in Van, Turkey. This study was approved by the in-
stitutional ethics committee of Yuzuncu Yıl University. Medical 
records of 249 women with a history of recurrent miscarriage 
were reviewed. They were tested for inherited thrombophilia 
between January 2010 and June 2015 in our tertiary refer-
ral center. From among them 121 women aged 18–45 with 
MTHFR gene polymorphism were selected into the study 
population. The polymorphism composed of MTHFR C677T 
and A1298C gene homozygosity or heterozygosity and com-
pound heterozygosity. The selected women were followed up 
at our obstetric unit during their pregnancy. The patients with 
anatomic, hormonal, chromosomal, infectious and autoim-
mune factors for recurrent miscarriage were excluded from 
the study. The laboratory genotyping of the MTHFR gene 
was performed by the Polymerase Chain Reaction which was 
performed by a Perkin Elmer 9600 and the profile consisted of 
an initial melting step of 2 min at 94°C; followed by 35 cycles 
of 30 s at 94°C, 30 s at 61°C, and 30 s at 72°C; and a final 
elongation step of 7 min at 72°C. The normal and mutant 
heterozygous or homozygous genotype profiles of each of 
the genes were determined using the enclosed CollectorTM 
sheet. Patients were divided into two groups: Anticoagulant 
free group (Group A) (n: 68) and anticoagulant therapy group 
(Group B) (n: 53). The women in group A received only oral 
folic acid (5 mg/day) and iron (80 mg elementary iron/day, 
iron [II] sulphate) during their pregnancy. The women in group 
B received oral folic acid (5 mg/day), iron (80 mg elementary 
iron/day, iron [II] sulphate) and prophylactic dose of LMWH 
(enoxaparin 40 mg/day or bemiparin 3500 IU/day, subcu-
taneously). LMWH therapy was started between 6th and 8th 
week of pregnancy and continued until delivery. The primary 
outcome was live birth. Among secondary outcomes there 
were early-late miscarriages, stillbirths, preterm births, con-
genital anomalies, obstetric complications and short-term 
neonatal events. These pregnancy outcomes of the patients 
were reviewed from the hospital’s medical records. 
RM was described as three or more consecutive spon-
taneous pregnancy losses before 22nd week of gestation 
(early or late miscarriage). All miscarriages were confirmed 
either by positive urine/serum HCG and sonography or 
histology of uterine curettage. Early miscarriage was de-
fined as a pregnancy loss at < 12 weeks of gestation. Late 
miscarriage was defined as a pregnancy loss between 12 and 
22 weeks of gestation. Stillbirth was defined as a pregnancy 
loss > 22 weeks of gestation. Intrauterine growth restriction 
(IUGR) was defined as a birthweight < 5th percentile [16]. 
Severe preeclampsia was described as blood pres-
sure > 160/110 mm Hg recorded at least 6 h apart and 
proteinuria > 5 gm in a 24-hour urine sample. In addition, 
any patient with cerebral or visual impairment, persistent 
epigastric pain, pulmonary edema or cyanosis was diag-
nosed with severe preeclampsia [17].
Descriptive statistics for the studied variables (char-
acteristics) were presented as Mean, Standard Deviation 
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values. Continuous variables were compared among the 
two groups using Student T-test. Z-ratio test was used to 
examine the association between categorical variables. Sta-
tistical significance levels were set to 5%. The SPSS (IBM SPSS 
Statistics for Windows, Version 22.0. IBM Corp. Released 
2013. Armonk, NY: IBM Corp.) statistical program was used 
for all statistical computations.
RESULTS
We obtained the records of 121 RM patients diagnosed 
with MTHFR gene polymorphism. 68 patients were in 
group A and 53 patients were in group B. Group A involved 
22 women with MTHFR A1298C heterozygous, 8 women 
with MTHFR A1298C homozygous, 12 women with MTHFR 
C677T heterozygous, 12 women with MTHFR C677T ho-
mozygous and 14 women with combination of MTHFR 
A1298C and MTHFR C677T heterozygous. Group B involved 
9 women with MTHFR A1298C heterozygous, 13 women 
with MTHFR A1298C homozygous, 8 women with MTHFR 
C677T heterozygous, 7 women with MTHFR C677T homozy-
gous and 16 women with combination of MTHFR A1298C 
and MTHFR C677T heterozygous. The clinical and obstetric 
outcomes of the patients were presented in Table 1. There 
was no significant difference between the groups in terms 
of maternal age, early miscarriage rate, late miscarriage 
rate, stillbirth rate, preterm birth rate, chorioamnionitis rate, 
preeclampsia rate and IUGR rate. The total live birth rate 
was 57.9% (70/121) in the study and this rate was higher in 
group B (48.5% vs. 69.8% respectively, p: 0.015). The total 
preterm birth rate was 22.3% (27/121) in the study. There 
was no significant difference between the groups in preterm 
delivery rate (16.2% [11/68] vs. 30.2% [16/53] respectively, 
p: 0.070). Also, extremely preterm (24–28 gestational weeks), 
very preterm (28–32 gestational weeks) and late preterm 
birth rates (32–36 gestational weeks) were similar between 
the groups (p: 0.653, p: 0.178, p: 0.403, respectively). The 
total IUGR rate was 5.8% (7/121) in the study and this rate 
was similar between each group (7.4% vs. 3.8% respectively, 
p: 0.465). The total congenital anomaly rate was 11.6% 
(14/121) in the study and congenital anomalies were more 
frequent in group A (17.6% vs. 3.8% respectively, p: 0.022). 
Group A involved 5 fetuses with neural tube defect, 3 fetuses 
with diaphragm hernia, 1 fetus with esophagus atresia, 
2 fetuses with non-immune hydrops fetalis and 1 fetus with 
hypo plastic left ventricle syndrome. In group B, only 2 fe-
tuses had neural tube defect. 
The delivery and short term neonatal outcomes of the 
patients were shown in Table 2. The total mean gestational 
age at birth was 33.81 ± 5.09 in the study. There were no 
significant differences between the groups in terms of ges-
tational age at birth, delivery type, delivery complications 
(fetal distress, prolonged labor, placental abruption, se-
vere preeclampsia and placenta previa), birthweight, Apgar 
scores and neonatal intensive care unit (NICU) admission. 
The total NICU admission rate was 19.0% (23/121) in the 
study. The total fetal distress, placental abruption and severe 
preeclampsia rates were as 17.4% (21/121), 5.0% (6/121) and 
3.3% (4/121), respectively in the study.
DISCUSSION
The current study demonstrated that unexplained RM 
patients with MTHFR gene polymorphism, who received 




(n = 53) p
Maternal age 28.40 ± 5.20 28.36 ± 5.77 0.969*
Number of early miscarriage 13/68 (13.1%) 6/53 (11.3%) 0.227#
Number of late miscarriage 16/68 (23.5%) 13/53 (24.5%) 0.899#
Number of stillbirth 13/68 (19.1%) 5/53 (9.4%) 0.120#
Preterm birth 11/68 (16.2%) 16/53 (30.2%) 0.070#
24–28 gestational weeks 6/68 (8.8%) 6/53 (11.3%) 0.653#
28–32 gestational weeks 3/68 (26.6%) 6/53 (38.9%) 0.178#
32–36 gestational weeks 2/68 (26.9%) 4/53 (33.3%) 0.403#
Chorioamnionitis 4/68 (4.4%) 2/53 (3.8%) 0.695#
Preeclampsia 6/68 (8.8%) 3/53 (5.7%) 0.730#
IUGR 5/68 (7.4%) 2/53 (3.8%) 0.465#
Congenital anomalies 12/68 (17.6%) 2/53 (3.8%) 0.022#
Live birth 33/68 (48.5%) 37/53 (69.8%) 0.015#
*Student T-test was used to compare continuous variables; #Z ratio test was used to compare categorical variables; LMWH (–) — low molecular weight heparin absent 
group; LMWH (+) — low molecular weight present group; IUGR — intrauterine growth restriction
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anticoagulant therapy (LMWH) during the period of their 
new pregnancy, had a lower risk for congenital anoma-
lies. Moreover, anticoagulant therapy improved the live birth 
rates among these patients. However, anticoagulant therapy 
did not have any beneficial effect on the rate of early-late 
miscarriages, stillbirth, preterm delivery, preeclampsia, IUGR, 
placental abruption, Apgar scores or NICU admission among 
these patients.
There is a debate on the usage of anticoagulant therapy 
in women with unexplained RM. Kaandorp et al. stated that 
aspirin or LMWH did not improve live birth rate in women 
with unexplained RM [18]. Similarly, the recent Cochrane 
review suggests that the live birth rate is not affected by 
LMWH treatment in unexplained RM patients [14]. In op-
position to that stands a recent study from Turkey report-
ing positive effects of LMWH on live birth rate in recurrent 
miscarriage patients who used LMWH when compared to 
patients without LMWH treatment [15]. Our study in turn 
shows that LMWH improves the live birth rate among RM 
patients with MTHFR gene polymorphism. The apparent 
heterogeneity of study populations in these different clini-
cal trials may be the origin for conflicting results. Further-
more, most of the studies mentioned above did not include 
women with MTHFR gene polymorphism [15, 18]. It is of 
vital importance that our study population is composed of 
selected groups of unexplained RM patients with different 
MTHFR gene polymorphisms.
Many previous studies reported that there were possible 
associations between MTHFR gene polymorphism (espe-
cially MTHFR C677T polymorphism) and fetal neural tube de-
fects. However, MTHFR gene polymorphism is not the main 
factor behind such congenital malformations. Moreover, 
maternal blood homocysteine levels can also be altered by 
some genetic and environmental factors [7, 8]. Yet, the fetal 
neural tube defect rate in our study was 5.9% (7/121), which 
is higher than in the general population (0.5–2/1000) [19]. 
RM is also associated with fetal anomalies [5]. Two clini-
cal trials compared congenital abnormalities in RM patients 
and they reported similar rates between patients that did 
and did not receive LMWH [20, 21]. In our study, congenital 
abnormalities were more frequent in LMWH-free group 
(group A). Although our study did not intend to investigate 
this issue, we did not reveal any association between these 
abnormalities and LMWH. Hence, such observation cannot 
be explained by the usage of LMWH. 
High levels of maternal homocysteine have been as-
sociated with preeclampsia and abruption of placenta [22, 
23]. It has been established that hyperhomocysteinemia is 
a contributor to endothelial dysfunction in pregnancy [23]. 
In a recent meta-analysis it was demonstrated that MTHFR 
C677T polymorphism was associated with preeclampsia 
in Asian and white population while MTHFR A1298C poly-
morphism had no such association [26]. Also, events like 
necrosis, acute and chronic inflammation or vascular throm-
bosis are more prominent in the deciduae of RM patients 
compared with normal pregnancies [27]. These factors are 
possible causes of late pregnancy complications like preec-
lampsia, placental abruption and late pregnancy complica-
tions in RM [5, 26]. Some randomized controlled trials de-
termined that LMWH is a preventive treatment for placenta 
mediated pregnancy complications [27, 28]. However, Mar-
tinelli et al. suggested that LMWH should not be routinely 
administered to prevent recurrence of placenta-mediated 
pregnancy complications [29]. Badawy et al. did not detect 




(n = 53) p
Delivery week 32.75 ± 5.16 34.88 ± 4.87 0.060*
Vaginal delivery 19/68 (27.9%) 14/53 (26.4%) 0.851#
Cesarean-section 22/68 (32.4%) 26/53 (49.1%) 0.256#
Fetal distress 10/68 (14.7%) 11/53 (20.8%) 0.390#
Prolonged labor 5/68 (7.4%) 10/53 (18.9%) 0.065#
Abruption of placenta 4/68 (5.9%) 2/53 (3.8%) 0.586#
Severe preeclampsia 2/68 (2.9%) 2/53 (3.8%) 0.802#
Placenta previa 1/68 (3.0%) 1/53 (2.7%) 0.861#
Birthweight 2174.14 ± 1140.20 2543.75 ± 1105.42 0.159*
Apgar 1. minute 5.28 ± 1.59 5.92 ± 1.12 0.056*
Apgar 5. minutes 6.78 ± 1.74 7.43 ± 1.04 0.059*
NICU admission 13/68 (19.1%) 10/53 (18.9%) 0.972#
*Student T-test was used to compare continuous variables; #Z ratio test was used to compare categorical variables; LMWH (–) — low molecular weight heparin absent 
group; LMWH (+) — low molecular weight present group; NICU — neonatal intensive care unit
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any therapeutic effect of LMWH on obstetric and neonatal 
complications in RM patients either [21]. Our results are in 
accordance with these studies. We did not find any beneficial 
effect of LMWH on obstetric or neonatal complications in 
the selected group of different MTHFR gene polymorphisms 
among RM patients. 
The present study has several limitations. The study is 
retrospective and small in sample size. We focused only on 
MTHFR gene polymorphism and the effects of anticoagulant 
use in RM patients without controlling for maternal folic 
acid and homocysteine concentrations. Also, we included 
all subgroups of MTHFR gene polymorphism, thus the het-
erogeneity of the study population may cause a potential 
bias. The clinicians advised different LMWH regimens to the 
patients according to their clinical experience, so we could 
not standardize the LMWH regimen. Some patients were 
administered enoxaparin and some bemiparin for LMWH 
prophylaxis. 
CONCLUSIONS
Based on the available evidence, the association be-
tween MTHFR gene polymorphism and RM, as well as the 
usage of LMWH for preventing obstetric complications or 
empiric anticoagulation for unexplained RM, all remain de-
batable topics in the literature. However, in current clinical 
practice many obstetricians all around Turkey still use anti-
coagulation treatment modalities for the aforementioned 
clinical indications. The current indiscriminate use of LMWH 
for all RM patients in Turkey should be changed according 
to the evidence based guidelines. In our opinion, specific 
subgroups of RM patients might benefit from new treatment 
strategies. As a result of this study, despite a limited number 
of patients, we propose that anticoagulation therapy be 
preferred for improving live birth rate in unexplained RM 
patients complicated with MTHFR gene polymorphism only. 
We also call for further studies to discriminate the effect of 
LMWH on the live birth rate in specific subgroups of MTHFR 
gene polymorphism (homozygous vs. heterozygous). We 
also conclude that in our patients selected from eastern re-
gion of Turkey with MTHFR gene polymorphism, the routine 
use of low molecular weight heparin did not improve the 
late pregnancy complications.
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